logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
R

Rebecca Taub

madrigal pharmaceuticals

71H指数
276论文数
2.1W被引数
收录论文 61
发表时间
logo
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trialresmetirom定量回归qFibrosis：来自MAESTRO-NASH III期临床试验的探索性组织学终点
errJournal of Hepatology
IF33
err2026-03-25
err0
errOAAI
errJörn M. Schattenberg; Pierre Bedossa; Cynthia D. Guy; Rebecca Taub; Dominic Labriola; Hang Zhang; James Hennan; Raul C. Camacho; Elaine Chng; Yayun Ren; Dean Tai; Stephen A. Harrison
err分享
err收藏
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis使用resmetirom治疗MASLD谱系患者（从早期MASH到MASH肝硬化）后的健康相关生活质量改善
errHepatology Communications
IF4.6
err2026-02-26
err0
errOAAI
errYounossi, Zobair M.; Nader, Fatema; Labriola, Dominic; Taub, Rebecca; Racila, Andrei; Henry, Linda; Stepanova, Maria
err分享
err收藏
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH TrialResmetirom对体重减轻和/或糖尿病患者代谢功能障碍相关非酒精性脂肪性肝炎的影响：一项MAESTRO-NASH试验的二次分析（患者同时接受胰高血糖素样肽-1受体激动剂和其他糖尿病疗法）
errAlimentary Pharmacology & Therapeutics
IF6.7
err2025-10-23
err0
errOAAI
errMazen Noureddin; Mary Rinella; Rebecca Taub; Dominic Labriola; Raul C. Camacho; Naim Alkhouri; Rohit Loomba; Meena B. Bansal
err分享
err收藏
The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis胆汁酸挑战试验量化了基线功能异质性，并评估了在MASH相关的Child-Pugh A级肝硬化中对Resmetirom的反应改善。
errGastro Hep Advances
IF0
err2025-10-01
err0
errOAAI
errAlkhouri, Naim; Mcrae, Michael P.; Taub, Rebecca; Hill, Brandon; Imperial, Joanne C.; Kittelson, John; Moussa, Sam E.; Everson, Gregory T.
err分享
err收藏
Treatment With Resmetirom for up to Two Years Led to Improvement in Liver Stiffness, Fibrosis Biomarkers, Fibrosis Scores, and Portal Hypertension Risk in 122 Patients With Compensated MASH Cirrhosis使用Resmetirom治疗长达两年，可改善122例代偿期MASH肝硬化患者的肝硬度、纤维化生物标志物、纤维化评分和门静脉高压风险。
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2025-10-01
err0
PREAI
errAlkhouri, Naim; Taub, Rebecca; Labriola, Dominic; Lu, Xiaomin; Moussa, Sam; Noureddin, Mazen
err分享
err收藏
Assessment of Resmetirom Efficacy (80 mg vs 100 mg) Stratified by Baseline Body Mass Index and Weight in Patients From the MAESTRO-NASH Trial
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2024-10-01
err0
PREAI
errNouredden, Mazen; Schattenberg, Joern M.; Taub, Rebecca; Labriola, Dominic; Loomba, Rohit
err分享
err收藏
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis
errHEPATOLOGY
IF15.8
err2024-09-06
err2
PREAI
errYounossi, Zobair M.; Stepanova, Maria; Racila, Andrei; Henry, Linda; Labriola, Dominic; Taub, Rebecca; Nader, Fatema
err分享
err收藏
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisResmetirom治疗NASH肝纤维化的3期随机对照试验
errNEW ENGLAND JOURNAL OF MEDICINE
IF78.5
err2024-02-08
err342
errOAAI
errHarrison, Stephen A.; Bedossa, Pierre; Guy, Cynthia D.; Schattenberg, Joern M.; Loomba, Rohit; Taub, Rebecca; Labriola, Dominic; Moussa, Sam E.; Neff, Guy W.; Rinella, Mary E.; Anstee, Quentin M.; Abdelmalek, Manal F.; Younossi, Zobair; Baum, Seth J.; Francque, Sven; Charlton, Michael R.; Newsome, Philip N.; Lanthier, Nicolas; Schiefke, Ingolf; Mangia, Alessandra; Pericas, Juan M.; Patil, Rashmee; Sanyal, Arun J.; Noureddin, Mazen; Bansal, Meena B.; Alkhouri, Naim; Castera, Laurent; Rudraraju, Madhavi; Ratziu, Vlad
err分享
err收藏
Relationship of non-invasive measures with histological response in patients with nonalcoholic steatohepatitis and fibrosis: 52-week data from the Phase 3 MAESTRO-NASH trial
errDIGESTIVE AND LIVER DISEASE
IF3.8
err2024-02-01
err2
PREAI
errMangia, A.; Loomba, R.; Schattenberg, J. M.; Taub, R.; Labriola, D.; Noureddin, M.; Ratziu, V.; Harrison, S. A.
err分享
err收藏
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trialResmetirom治疗非酒精性脂肪性肝病: 一项随机，双盲，安慰剂对照的3期试验
errNATURE MEDICINE
IF50
err2023-10-16
err112
errOAAI
errHarrison, Stephen A.; Taub, Rebecca; Neff, Guy W.; Lucas, K. Jean; Labriola, Dominic; Moussa, Sam E.; Alkhouri, Naim; Bashir, Mustafa R.
err分享
err收藏
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
errALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
err2023-10-02
err42
errOAAI
errHarrison, Stephen A.; Ratziu, Vlad; Anstee, Quentin M.; Noureddin, Mazen; Sanyal, Arun J.; Schattenberg, Joern M.; Bedossa, Pierre; Bashir, Mustafa R.; Schneider, David; Taub, Rebecca; Bansal, Meena; Kowdley, Kris V.; Younossi, Zobair M.; Loomba, Rohit
err分享
err收藏
HRS/SRp40-mediated inclusion of the fibronectin EIIIB exon, a possible cause of increased EIIIB expression in proliferating liver
errMOLECULAR AND CELLULAR BIOLOGY
IF2.7
err2023-03-29
err68
errOAAI
errDu, KY; Peng, Y; Greenbaum, LE; Haber, BA; Taub, R
err分享
err收藏
Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBPβ and mitogen-activated protein kinase/extracellular signal-regulate kinase regulation
errMOLECULAR AND CELLULAR BIOLOGY
IF2.7
err2023-03-27
err98
errOAAI
errLeu, JI; Crissey, MAS; Craig, LE; Taub, R
err分享
err收藏
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
errCLINICAL GASTROENTEROLOGY AND HEPATOLOGY
IF12
err2022-06-01
err38
PREAI
errYounossi, Zobair M.; Stepanova, Maria; Taub, Rebecca A.; Barbone, Jordan Mark; Harrison, Stephen A.
err分享
err收藏
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH
errHEPATOLOGY COMMUNICATIONS
IF4.6
err2021-01-04
err114
errOAAI
errHarrison, Stephen A.; Bashir, Mustafa; Moussa, Sam E.; McCarty, Kevin; Pablo Frias, Juan; Taub, Rebecca; Alkhouri, Naim
err分享
err收藏
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
errLANCET
IF88.5
err2019-11-01
err462
PREAI
errHarrison, Stephen A.; Bashir, Mustafa R.; Guy, Cynthia D.; Zhou, Rong; Moylan, Cynthia A.; Frias, Juan P.; Alkhouri, Naim; Bansal, Meena B.; Baum, Seth; Neuschwander-Tetri, Brent A.; Taub, Rebecca; Moussa, Sam E.
err分享
err收藏
MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
errJOURNAL OF HEPATOLOGY
IF33
err2018-04-01
err21
PREAI
errHarrison, S.; Moussa, S.; Bashir, M.; Alkhouri, N.; Frias, J.; Baum, S.; Tetri, B.; Bansal, M.; Taub, R.
err分享
err收藏
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome
errATHEROSCLEROSIS
IF5.7
err2015-05-01
err57
PREAI
errGaztanaga, Juan; Farkouh, Michael; Rudd, James H. F.; Brotz, Tilmann M.; Rosenbaum, David; Mani, Venkatesh; Kerwin, Todd C.; Taub, Rebecca; Tardif, Jean-Claude; Tawakol, Ahmed; Fayad, Zahi A.
err分享
err收藏
Protein tyrosine phosphatase of liver regeneration-1 is required for normal timing of cell cycle progression during liver regeneration
errAMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
IF3.3
err2015-01-15
err17
errOAAI
errJiao, Yang; Ye, Diana Z.; Li, Zhaoyu; Teta-Bissett, Monica; Peng, Yong; Taub, Rebecca; Greenbaum, Linda E.; Kaestner, Klaus H.
err分享
err收藏
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
errJOURNAL OF MEDICINAL CHEMISTRY
IF6.8
err2014-04-08
err132
PREAI
errKelly, Martha J.; Pietranico-Cole, Sherrie; Larigan, J. Douglas; Haynes, Nancy-Ellen; Reynolds, Charles H.; Scott, Nathan; Vermeulen, John; Dvorozniak, Mark; Conde-Knape, Karin; Huang, Kuo-Sen; So, Sung-Sau; Thakkar, Kshitij; Qian, Yimin; Banner, Bruce; Mennona, Frank; Danzi, Sara; Klein, Irwin; Taub, Rebecca; Tilley, Jefferson
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
A
Arun J. Sanyal
H 指数: 166 · 论文数: 1.4K
A
Andrew T. Hattersley
H 指数: 161 · 论文数: 1.3K
R
Rohit Loomba
H 指数: 154 · 论文数: 1.3K
Z
Zobair M. Younossi
H 指数: 140 · 论文数: 1.5K
M
Mitchell A. Lazar
H 指数: 138 · 论文数: 408
查看更多